Amicus Therapeutics (FOLD)

Executive Summary

Amicus Therapeutics is a global biotechnology company dedicated to developing transformative therapies for rare diseases, with a particular focus on lysosomal storage disorders. The company's lead commercial product, Galafold (migalastat), is approved for Fabry disease and continues to drive revenue. Amicus's pipeline is anchored by cipaglucosidase alfa plus miglustat (AT-GAA) for late-onset Pompe disease, currently in a pivotal Phase 3 study (PROPEL). Top-line results from this study are expected in the second half of 2026, representing a major near-term catalyst. If positive, the data would support regulatory filings in the US and EU, potentially expanding Amicus's commercial footprint. Additionally, the company is exploring next-generation enzyme replacement therapies and earlier-stage programs. Financially, Amicus has a solid commercial base from Galafold, which should help fund pipeline advancement. However, the stock is subject to binary event risk around the PROPEL readout. Overall, Amicus presents a risk/reward profile typical of a mid-cap biotech, with the potential for significant value creation if the Pompe therapy succeeds.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 PROPEL Study Top-Line Results for AT-GAA in Pompe Disease75% success
• Q1 2027Regulatory Submission (NDA/BLA) for AT-GAA70% success
• Q2 2026Commercial Update on Galafold Sales Trajectory90% success